drugset
Drugs / Surzebiclimab
last change Jul 2026 re-read 9 days ago

Surzebiclimab

also known as BGB-A425

Monoclonal antibody

Developed for
head and neck squamous cell carcinoma · cancer
Investigated by
BeiGene · BeOne Medicines

Trials 3

today NCT05909904 · Ph 2 NCT04164199 · Ph 3 NCT03744468 · Ph 1/2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03744468 Nov 2018 → Feb 2025 head and neck squamous cell carcinoma BeiGene Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05909904 Aug 2023 → Jun 2025 head and neck squamous cell carcinoma BeiGene Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04164199 Dec 2019 → May 2026 cancer BeOne Medicines Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2024-03-06 BeOne Medicines Results BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 beonemedicines.com ↗
An additional preclinical presentation highlights the therapeutic potential of the triple-combination of tislelizumab with anti-LAG-3 (LBL-007) and anti-TIM-3 (surzebiclimab); this combination is being evaluated in an ongoing Phase 2 study in head and neck squamous cell carcinoma (NCT05909904).

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Surzebiclimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04164199 ↗
1

NCT03744468 ↗
Known as BGB-A425 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909904 ↗
Action Inhibit “surzebiclimab (anti TIM-3)” NCT03744468 ↗
Modality Monoclonal antibody — CHEMBL4594464 ↗
Route Intravenous “surzebiclimab 2 mg intravenous (IV) infusion on day 1 of each cycle” NCT03744468 ↗